AIDS Therapies (IL-2)

Drug Immunotherapy Boosts Immune Cell Levels in HIV Patients

Published in AIDS Weekly, April 14th, 1997

Chiron Corp., Emeryville, California, announced that outpatient subcutaneous administration of recombinant interleukin (IL-2) in people infected with HIV can produce substantial and sustained increases in CD4 cells levels.

The data was released according to a study reported in the April 1997 issue of the Journal of Infectious Diseases by Richard Davey, M.D., Clifford Lane, M.D. and their colleagues at the U.S. National Institutes of Health (NIH). These results corroborated the findings from another NIH study with IL-2 in HIV, reported in the October 31, 1996, issue of the New England Journal of Medicine, in which the NIH researchers showed that in some patients,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry